Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of an Optimized Dual GLP-1/GIP Receptor Agonist (BGM0504) in Healthy Subjects-A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study

被引：0
|
作者：
Yuan, Jiandong
Huang, Yangqing
Ding, Haifeng
Jiang, Xiaohui
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-849-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
849-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo- controlled study
    Harrison, Stephen A.
    Browne, Sarah K.
    Suschak, John J.
    Tomah, Shaheen
    Gutierrez, Julio A.
    Yang, Jay
    Roberts, M. Scot
    Harris, M. Scott
    JOURNAL OF HEPATOLOGY, 2025, 82 (01)
  • [42] A Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136, a Novel Long-Acting Glucagon Analogue, in Healthy Subjects
    Huh, Ki Young
    Shin, Wonjung
    Baek, Eunhye
    Seo, Sujin
    Lee, Woosun
    Baek, Seungjae
    Lee, Howard
    DIABETES, 2020, 69
  • [43] Safety, Tolerability, and Pharmacokinetics of Therapeutic and Supratherapeutic Doses of Tramadol Hydrochloride in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Multiple-Ascending-Dose Study
    DeLemos, Byron
    Richards, Henry M.
    Vandenbossche, Joris
    Ariyawansa, Jay
    Natarajan, Jaya
    Alexander, Binu
    Ramakrishna, Tage
    Murtaugh, Thomas
    Stahlberg, Hans-Juergen
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (06): : 592 - 603
  • [44] Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study
    Risinger, Robert
    Bhagwagar, Zubin
    Luo, Feng
    Cahir, Matthew
    Miler, Laura
    Mendonza, Anisha E.
    Meyer, Jeffrey H.
    Zheng, Ming
    Hayes, Wendy
    PSYCHOPHARMACOLOGY, 2014, 231 (11) : 2299 - 2310
  • [45] Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study
    Robert Risinger
    Zubin Bhagwagar
    Feng Luo
    Matthew Cahir
    Laura Miler
    Anisha E. Mendonza
    Jeffrey H. Meyer
    Ming Zheng
    Wendy Hayes
    Psychopharmacology, 2014, 231 : 2299 - 2310
  • [46] Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
    Roux, Carel W. le
    Steen, Oren
    Lucas, Kathryn J.
    Startseva, Elena
    Unseld, Anna
    Hennige, Anita M.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (03): : 162 - 173
  • [47] SAFETY OF AMISELIMOD IN HEALTHY SUBJECTS: RESULTS FROM A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Hanauer, Stephen
    O'Reilly, Terry
    Lester, Robert
    Slatkin, Neal
    Lee, Jimin
    Franklin, Howard
    Bulawski, Angela
    Israel, Robert
    GASTROENTEROLOGY, 2021, 160 (03) : S1 - S2
  • [48] SAFETY OF AMISELIMOD IN HEALTHY SUBJECTS: RESULTS FROM A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Hanauer, Stephen
    O'Reilly, Terry
    Lester, Robert
    Slatkin, Neal
    Lee, Jimin
    Franklin, Howard
    Bulawski, Angela
    Israel, Robert
    INFLAMMATORY BOWEL DISEASES, 2021, 27 : S1 - S1
  • [49] Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects
    Guptill, Jeffrey T.
    Raja, Shruti M.
    Boakye-Agyeman, Felix
    Noveck, Robert
    Ramey, Sarah
    Tu, Tian Ming
    Laskowitz, Daniel T.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (06): : 770 - 776
  • [50] Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men
    Scott, Graham
    Ahmad, Irfan
    Howard, Katy
    MacLean, David
    Oliva, Cristina
    Warrington, Steve
    Wilbraham, Darren
    Worthington, Paul
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 381 - 391
12345